This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the Information for Authors.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.
Synthesis and anticancer activity evaluation of $\eta^5$-C$_5$(CH$_3$)$_4$R ruthenium complexes bearing chelating diphosine ligands†

A. Rodríguez-Bárázno, a R. M. Lord, a A. M. Basri, a R. M. Phillips, b A. J. Blacker a and P. C. McGowan a

The complexes [RuCp*(PP)Cl] (Cp* = C$_5$Me$_5$ [1], PP = dppm; [4], PP = Xantphos), [RuCp*(PP)Cl] (Cp* = C$_5$Me$_5$(CH$_2$)$_2$OH; [2], PP = dppm; [5], PP = Xantphos) and [RuCp*(dppm)(CH$_2$CN)][SbF$_6$] [3] were synthesized and evaluated in vitro as anticancer agents. Compounds 1-3 gave nanomolar IC$_{50}$ values against normoxic A2780 and HT-29 cell lines, and were also tested against hypoxic HT-29 cells, maintaining their high activity. Complex 3 yielded an IC$_{50}$ value of 0.55 ± 0.03 µM under a 0.1% O$_2$ concentration.

Numerous organometallic ($\eta^5$-arene)-ruthenium complexes have been screened as anticancer agents with promising results, for instance, compounds of the types [(η5-arene)Ru(NN)Cl] (NN = chelating nitrogen ligands, especially ethylenediamine (en)),[(η5-arene)Ru(NO)Cl] [NO = 3′-fluorophenyl-2-buten-1-one],[4] [(η5-arene)Ru(OO)Cl] [OO = 3-hydroxyflavone derivatives, X = Cl, Br or I],[5-6] or [(η5-arene)Ru(pta)Cl$_2$] (RAPTA) [pta = 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decaene).[7,8] Samuelson and co-workers have published the use of $\eta^5$-p-cymene ruthenium complexes with different diphosines acting as either monodentate or chelating ligands, which showed good growth inhibitions against several cancer cell lines. In contrast, fewer examples of $\eta^5$-cyclopentadienyl (Cp) or pentamethylcyclopentadienyl (Cp*) compounds have been biologically evaluated. Sava reported the synthesis and activity against TS/A adenocarcinoma of the compounds [(η5-C$_5$H$_5$)Ru(pta)Cl] and [(η5-C$_5$Me$_5$)Ru(pta)Cl], as equivalents to the RAPTA complexes. Compounds of the type [(η5-C$_5$H$_5$)Ru(PP)L][X] (PP = 2 × PPh$_3$ or 1,2-bis(diphenylphosphino)ethane, L = planar nitrogen σ-bonded ligand and X = CF$_3$SO$_3$ or PF$_6$) have been synthesised by Moreno et al. and some of them show better cytotoxicities than cisplatin. However, none of these Cp/Cp* ruthenium complexes has been tested under hypoxic conditions. Some diphosines have demonstrated cytotoxicity against various cell lines, but it has been observed that, upon coordination to metals, diphosines produce complexes with improved anticancer activity compared to the free ligands; a general hypothesis considers that the metal protects the ligands from oxidation before they interact with the corresponding biological target.

Here we present the results obtained from cell line assays carried out under normoxic and hypoxic conditions with ruthenium complexes containing chelating diphosine ligands such as 1,1-bis(diphenylphosphino)methane (dppm) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos). The complexes have general structures [RuCp*(PP)Cl] (1, PP = dppm; 4, PP = Xantphos), [RuCp*(PP)Cl] (Cp* = C$_5$Me$_5$(CH$_2$)$_2$OH; 2, PP = dppm; 5, PP = Xantphos) and [RuCp*(PP)(CH$_2$CN)][SbF$_6$] (3, PP = dppm). We investigated the biological activity of both ligands and the effect of complexation. We were interested in assessing the impact of hydrophilic functionalisation of Cp* with an –OH group and the different cytotoxicities shown by analogous neutral and charged complexes. The anticancer activities were assessed against A2780 and HT-29 cell lines, for HT-29 both at 21% and 0.1% O$_2$ (hypoxic conditions) concentrations. Complexes 1 and 4 were synthesised from [RuCp*(Cl)$_2$], which was obtained following literature methods. A similar method was employed for compounds 2 and 5, starting from the novel [RuCpCl$_2$] complex (Scheme 1). This in turn was prepared by reaction of (5-hydroxypentyl)-tetramethylcyclopentadiene with RuCl$_3$ in ethanol at reflux. Compounds 1, 2 and 4 had been previously reported, but not biologically tested. Complex 3 was obtained from complex 1, acetonitrile and NaSbF$_6$ in methanol at room temperature (Scheme 2). This method was adapted from the published synthesis of [RuCp*(PP)(CH$_2$CN)][PF$_6$] complexes, where PP = chiral diphosines. The structure of complex 3 was determined by single crystal X-ray diffraction. Compound 3 crystallised in a triclinic cell from pentane/chloroform, and the structural solution was performed in the space group $\overline{P1}$. The asymmetric unit comprises one molecule of compound 3, including the counterion SbF$_6$. The molecular structure of 3 is shown in Figure 1 and selected bond lengths and angles are given in Table 1. Compound 3 presents the characteristic piano-stool geometry typical of $\eta^2$- and $\eta^5$-organometallic ruthenium species. The (N1-C11) triple bond length is 1.153(2) Å. The cytotoxic activities of compounds 1-5, along with cisplatin, dppm and Xantphos were tested on the A2780 and HT-29 cell lines after five-day exposures at 37 °C and 21% O$_2$. The IC$_{50}$ results are shown in Table 2. The most active complexes were those formed from dppm, 1, 2 and 3, all with better cytotoxicities, in the nanomolar range, than cisplatin for both HT-29 and A2780 cell lines.

Cite this: DOI: 10.1039/x0xx00000x

Received 00th January 2012,
Accepted 00th January 2012

DOI: 10.1039/x0xx00000x

www.rsc.org/
Dppm was active by itself, with IC<sub>50</sub> values below 1.5 μM. However, <sup>1</sup>H and <sup>31</sup>P NMR spectroscopy experiments in deuterated DMSO showed no de-coordination of dppm from complexes 1 and 3 after five days. The observation that diphosphines do not dissociate is further reinforced by the fact that complexes 4 and 5 gave moderate to good activities, which are not due to a possible release of the ligand, because Xantphos did not show anticancer behaviour on its own. This contradicts the previous hypothesis that the activities of these types of diphosphine complexes depend on possible de-coordinations of the ligands. The extremely different behavior of dppm and Xantphos provides interesting material for further future studies. Complexes 4 and 5 were more active against A2780 cells, with IC<sub>50</sub> values close to cisplatin. The presence of the (CH<sub>3</sub>)<sub>2</sub>OH chain in the Cp<sup>+</sup> compounds 2 and 5 produced no great effect on their anticancer activities, compared to those of the Cp<sup>+</sup> complexes 1 and 4. The best cytotoxicity was observed for the positively charged complex 3.

![Scheme 1. General synthesis of complexes 1, 2, 4 and 5.](image1)

![Scheme 2. Synthesis of complex 3.](image2)

**Figure 1.** ORTEP structure of complex 3 (cation) with thermal ellipsoids set at 50% probability. Hydrogen atoms omitted for clarity.

Table 2 gives the IC<sub>50</sub> results obtained for the most active compounds 1-3 against hypoxic HT-29 cells at an oxygen concentration of 0.1%. Cancerous cells are known to proliferate within hypoxic environments, with oxygen content below 2%, therefore hypoxic experiments tend to reproduce the conditions found in human solid tumours. Apart from cisplatin, whose activity remains practically unmodified, tirapazamine, a drug known to be hypoxia sensitive, was also employed as reference. Interestingly, the IC<sub>50</sub> of dppm under hypoxic conditions increased considerably from 1.47 μM to 17.19 μM. A possible explanation for this is that the active species might be an oxidized form of dppm. However, Samuelson et al. have reported that, while dppm is moderately active against H460 lung cells (IC<sub>50</sub> = 18.2 μM), mono-oxidised dppm shows no cytotoxic activity (IC<sub>50</sub> > 250 μM), and similar conclusions had been drawn by Sadler et al. The activities of complexes 1-3 improved slightly at a low O<sub>2</sub> concentration. Complex 3 showed again the best performance, with an IC<sub>50</sub> of 0.55 ± 0.03 μM, and is of particular significance and interest.

**Table 1.** Selected bond lengths [Å] and angles [°] in the structure of compound 3 with s.u.s. in parenthesis.

**Table 2.** IC<sub>50</sub> values for complexes 1-5 along with cisplatin, tirapazamin, dppm and Xanthos. The drugs were incubated for 5 days at 37°C.

**Table 3.** IC<sub>50</sub> values for complexes 1-3 along with cisplatin, tirapazamin, dppm and Xanthos. The drugs were incubated for 5 days at 37°C.
Conclusions

In summary, a series of Cp*-based diphosphine ruthenium complexes (1-5) was prepared and biologically tested against A2780 and HT-29 cancerous cell lines. Both normoxic and hypoxic studies showed activities in the nanomolar range. The best anticancer activity was obtained with complex 3, which maintained a low IC50 value even under hypoxic conditions with 0.1% O2 concentration, and showed a higher degree of hydrolysis than its neutral analogue 1 under the same conditions. Future studies could include cationic versions of 2, 4, 5 and similar complexes to check whether they are more effective. Testing other free and coordinated phosphines and phosphine oxides could shed some light on the effect that the oxidation state and structure of the ligand have on cytotoxic activity.

Notes and references

† We wish to acknowledge Technology Strategy Board for funding.
Electronic Supplementary Information (ESI) available: experimental procedures for compounds, cell line experimental and crystal structure determination details (CCDC 957987). See DOI: 10.1039/c000000x/

A series of ruthenium complexes with \( \eta^5\)-C\(_{5}\)(CH\(_3\))\(_4\)R and diphosphine ligands have been synthesised and evaluated \textit{in vitro} as anticancer agents. IC\(_{50}\) values in the nanomolar range have been obtained against two types of cell lines.